Under the multi-year collaboration, Cartography's proprietary computational and genomics platform will be utilized to discover and validate novel tumor-selective target antigens and pairs of antigens. Cartography's ATLAS and SUMMIT platforms integrate single-cell data from a comprehensive healthy reference and tumor atlas - applying target identification algorithms to identify single or pairs of targets that are most specific to the intended target cells and optimized for therapeutic programs. Gilead can opt in on multiple targets identified through this collaboration and will undertake all further research, development, and commercialization of programs against those targets.
'We are excited to partner with Gilead to identify novel and compelling antigen targets using our ATLAS and SUMMIT platforms,' said
Under the terms of the agreement, Cartography will receive an upfront payment of
About Cartography Biosciences
Cartography Biosciences is building a differentiated oncology pipeline of antibody-based therapies designed to target tumors more precisely than existing therapeutics. Cartography's ATLAS and SUMMIT drug discovery platforms are powered by an industry-leading, fully integrated dataset spanning over a thousand cell types across the healthy body and large-scale profiling of individuals cells from patient tumors. By leveraging petabytes of proprietary data, along with insights from machine learning and AI, Cartography is identifying and developing therapeutics against highly specific targets and target pairs to build a pipeline of molecules with the greatest patient impact. Cartography's lead program in preclinical development, CB21, is a T-cell engager being advanced for colorectal cancer (CRC).
Contact:
Email: hello@cartography.bio
Email: bd@cartography.bio
Tel: 833-318-4749
(C) 2024 Electronic News Publishing, source